Your search for esrd returned 63 results

Being overweight or obese as an adolescent is significantly associated with increased risk for all-cause treated end-stage renal disease (ESRD).

Kidney stones correlate with an increased risk of adverse kidney outcomes, including end-stage renal disease (ESRD), Stage 3b-5 chronic kidney disease, and sustained doubling of serum creatinine, but increases in absolute rates are small.

The lifetime risk of developing end-stage renal disease (ESRD) is higher for men than women, at all ages and estimated glomerular filtration rate (eGFR) strata.

In U.S. dialysis centers treating end-stage renal (ESRD) patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, vancomycin is overprescribed, despite evidence of lower rates of hospitalization and death in cefazolin-treated patients.

Intensive glucose therapy significantly reduces microalbuminuria and macroalbuminuria in adults with type 2 diabetes, but does not improve clinical renal outcomes.

Excess mortality rates persist among adults with young-onset diabetes, and are mainly due to end-stage renal disease (ESRD) and coronary artery disease (CAD).

Long-term daily use of fenofibrate is beneficial for patients with type 2 diabetes and moderate renal impairment and is not associated with an increase in drug-related safety concerns compared with those with mild renal impairment.

Keryx Biopharmaceuticals announced positive final data from its Phase 3 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis.

Pfizer announced results from two of its Phase 3 studies, ORAL Standard and Oral Step, of tofacitinib (CP-690,550) for the treatment of active rheumatoid arthritis.

The labeling for Onglyza (saxagliptin; Bristol-Myers Squibb) has been updated to include data from two clinical trials: a study of Onglyza in patients with moderate to severe renal impairment or end-stage renal disease (ESRD) and a second comparator study of Onglyza + metformin versus glipizide + metformin.